"In Switzerland, we often sell promising technologies too early"
This is custom heading element
Interview: Thomas Brenzikofer
Mr Claesson, what was behind your decision to get on board with Clinerion?
Ulf Claesson: Clinerion was originally an IT platform with a complicated name. Its founders hit upon the idea of building a large data hub for the pharmaceutical and healthcare industries. That was quite an ambitious idea. I reckon that the WHO or the Bill and Melinda Gates Foundation could possibly manage it. But a small company in Basel? As an IT person, I quickly saw how good the core technology was. What wasn’t clear, however, was the problem that the technology was going to solve. So we started working on that and felt our way slowly but surely towards the patient recruitment use case. Today, we are the only company in the world able to identify in real time from millions of patient data records those patients who are suitable for a specific clinical trial.
So you have aligned the company with a particular niche?
Yes, absolutely. When you are building a company, you must concentrate on solving a genuine problem. Our technology gives the customer clear benefits. Finding patients usually takes months, sometimes years. We cut this to weeks, or less. We ensure that a pharma company, hospital or contract research organisation already before the start of a clinical trial knows exactly where candidate patients are located and exactly how many there are. Depending on the goal, the study protocol can then be optimised as required. Because we avoid guesswork and identify genuine patients who meet the study criteria in this very moment, the study design is robust and risk is minimised. Not only that, but a study sponsor knows exactly where and how many of his “sites” he must place. Real-time information is particularly valuable for this. As soon as I activate a study protocol, the doctors involved are notified and can call their patients in.
Is it easy to convince hospitals to collaborate with Clinerion?
We were rather naive about this at first. From an IT perspective, it makes sense to do everything in the cloud. That is exactly what we tried to do, but most people were negative about it. We also found that attitudes to data protection, as well as the regulations themselves, vary considerably from one country to the next. These factors make a cloud solution virtually impossible to implement. Today, we are installing a hardware appliance within a hospital’s IT infrastructure. The data therefore remains exactly where it is collected and it is as secure as all other patient data. We can also only access consolidated and aggregated meta information, which earns us the trust of decision-makers and the people using the system.
What exactly motivates hospitals to disclose their data?
We all basically share the same objective of providing relevant patients with drugs as soon as possible. We play a role in achieving this. The university hospitals are carrying out research to some extent for their own interests. We help them to carry out their internal studies more quickly. The pharmaceutical companies remunerate the hospitals for each patient who participates in a study. The doctors feel that participating in interesting studies is important. In our experience, the number of studies that hospitals are offered increases significantly as soon as they start working with us.
How many patients do you currently have access to?
We have access to 35 million patients via the hospitals. And we certainly need that many. The numbers can start dwindling rapidly depending on the symptoms you are searching for.
You operate mainly in emerging markets such as Brazil and Turkey. Why is that?
With the exception of the UK, Europe is more cautious about taking part in clinical trials. By 2020, Turkey expects to have increased the EUR 50 million turn-over in clinical trials in 2014 to EUR 1.5 billion. In Brazil, they are even changing the law to make it easier for pharmaceutical companies to carry out more studies in the future. In clinical trials, it is important for all participating patients to receive the same standard of care. Participants in trials might therefore receive better care than usual. This applies to some countries in Eastern Europe, for example. For some patients, this can be an incentive.
Does your data acquisition prioritise emerging markets?
No, not exclusively. We are also well positioned in a number of European countries. But we can certainly do better. We would also like to expand our presence in India and Taiwan, for example. Great Britain is a key focus for us and our partnership with Cisiv will help here. We recently entered into a partnership with this UK company. Cisiv’s platform complements our screening programme perfectly.
It sounds like a data contest. How close is your main competition?
There are three competitors. But we are the only ones able to provide real-time results. Our competition in the USA, however, has access to much more capital. At the last investment round, one of our competitors raised 32 million dollars.
Do you find it difficult to compete with that?
It is certainly difficult for an ICT start-up in Switzerland to obtain those kinds of amounts. We are not completely dependent on external investment, however. We have a very loyal shareholder base and have sufficient funding, even though we are still a long way from being profitable.
Could a sale be on the cards?
Our vision is to provide patients with medicines. If we see that we can achieve this goal more quickly, we would be willing to consider it. But selling is not currently under consideration. I have already founded a number of companies. Some were sold too early, even though we could still have helped them progress through one or more growth phases. I am convinced that Clinerion will succeed in that regard.
Do you consider the lack of growth financing to be a problem for the Swiss start-up scene?
Most certainly. Good technologies tend to be sold off too early because their owners cannot find the money they need for the next major milestone, typically for the global expansion phase.
What do you suggest?
Imitating Silicon Valley will get us nowhere. Also because costs there are unacceptably high at the moment. We really need to focus on our strengths. Just to give you one example: twice as many startups are established at ETH Zurich each year than at UC Berkeley. When universities foster a supportive environment, a start-up community develops all on its own. The students I meet at ETH are ambitious and full of energy. I also note, however, that many Swiss students prefer the security of working in a large corporation. We need a greater willingness to accept risk. We need to work on it.
How do you see innovation hub Basel?
We have good access to the sector here, and we can also recruit staff from neighbouring Germany. The labour market is therefore less competitive than in Zurich for example. We feel right at home here in Basel.
Interview: Thomas Brenzikofer and Annett Altvater
About Ulf Claesson
Ulf Claesson studied production technology at Chalmers University in Gothenburg and also gained a management degree at the University of St. Gallen. He worked for IBM and Hewlett-Packard, established spin-offs for various companies, and founded his own start-ups. In his lecture on “Technology Entrepreneurship” he passes on his experience as a “serial entrepreneur” to students at ETH. He is a member of the board of directors of various companies, the Foundation Board Director of the AO Foundation, and has been the CEO of Clinerion since 2012.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More